вЂњWe believe that lower drug exposure may be contributing to less-than-optimal treatment outcomes for some patients treated with Evrysdi. 4, 5 The goal of treatment in SMA is to sufficiently protect motor neurons and help preserve function. Over time, people with SMA may lose their ability to perform everyday activities, including brushing their teeth, turning on a light switch or drinking from a cup. People with SMA do not produce enough survival motor neuron (SMN) protein, which is critical for the ongoing maintenance of motor neurons that support sitting, standing and movement. The ASCEND study is designed to evaluate the clinical outcomes and assess the safety of a higher dose of nusinersen* in children, teens and adults with later-onset spinal muscular atrophy (SMA) following treatment with Evrysdi В® (risdiplam).

(Nasdaq: BIIB) today announced plans to initiate a global Phase 3b clinical study, ASCEND.

Building on the proven efficacy and well-established safety of the currently approved 12-milligram dose, patients in this study will receive an investigational higher dose of nusinersen, which is also being evaluated in the DEVOTE studyД¬AMBRIDGE, Mass., Sept.

The ASCEND study aims to evaluate whether treatment with a higher dose of nusinersen has the potential to improve clinical outcomes in these patients.

Clinical data available to date suggest there are remaining unmet needs in some spinal muscular atrophy (SMA) patients treated with Evrysdi 1 -3.

The fever code epub download